Investigation of the association of CTRB2 exon 6 deletion with time to progression and overall survival in pancreatic ductal adenocarcinoma. This is an ASCO Meeting Abstract from the 2025 ASCO ...

DelveInsight’s c-MET-NSCLC pipeline report depicts a robust space with 20+ active players working to develop 20+ pipeline ...

Naporafenib is Erasca’s main candidate, and it has Fast Track status for NRASm melanoma. See why I rate ERAS stock as a buy.

Levi Garraway, Roche’s chief medical officer and head of global product development, said: “The INAVO120 overall survival ...

Genialis, the RNA biomarker company, today announced an extension of its collaboration with Debiopharm, a Swiss-based global biopharmaceutical company, to develop a predictive biomarker for ...

The FDA approved a wide range of therapies in 2024, including many new molecular entities and biological products.

Application of seasonal auto-regressive integrated moving average model in forecasting the incidence of hand-foot-mouth disease in Wuhan, China. 'Outbreak Gold Standard' selection to provide ...

Discussions also delved into the complexities of value-based oncology care, the growing role of real-world data, and strategies to improve access to care in hematology. Across all sessions, a common ...

Oncogenesis is the process through which healthy cells become transformed into cancer cells. It is characterized by a series of genetic and cellular changes, including oncogene activation, that ...